San Diego-dependent Viking Therapeutics marked alone as a significant competitor inside the weight loss drug sector in February following revealing promising information from a mid-phase trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when provided like a weekly injection and in March the co